Chinese vaccine maker producing hepatitis B, HPV (under GSK license) and other vaccines for the domestic market.
Chinese vaccine maker producing hepatitis B, HPV (under GSK license) and other vaccines for the domestic market.
Sells vaccines mainly to provincial disease-control centres, which distribute them to local clinics: government-program vaccines are bought at tendered prices, while optional ones are paid for by the person vaccinated. Exposure to optional vaccines such as HPV and pneumococcal shots depends on consumer willingness to pay.
In one line: A Chinese vaccine maker partnered with GSK for HPV.
Moat: narrow (regulatory licence, distribution). Exclusive domestic distribution of GSK's Cervarix HPV vaccine plus its own vaccine manufacturing base.
Headquarters: Shenzhen, China · Employees: 1,957
Size Shenzhen Kangtai Biological Products (300601.SZ) is a China Health Care company (Biotechnology) with a market value of $1.86B, the 1247th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.41 on 18 Nov 2026.
Performance Over six months the shares fell 19.9%, against -3.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 19 in its peer set.
Growth Revenue fell 9.1% over the last twelve months (peer median +18.8%); the operating margin is 5.8% (peer median -58.6%).
Valuation It trades at 105.5× forward earnings against a peer median of 18.1× (most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.3 points below its cost of capital (10.0% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.45B | CN¥2.66B | CN¥2.64B | CN¥3.46B | CN¥3.15B |
| Revenue growth | — | +1% | -24% | +10% | — |
| Gross profit | CN¥1.91B | CN¥1.74B | CN¥1.97B | CN¥2.84B | CN¥2.56B |
| EBITDA | n/a | CN¥468M | CN¥469M | CN¥1.02B | CN¥431M |
| Net income | CN¥117M | CN¥70.3M | CN¥202M | CN¥861M | -CN¥133M |
| Free cash flow | CN¥180M | CN¥499M | CN¥188M | CN¥375M | -CN¥720M |
| Capital expenditure | CN¥441M | CN¥332M | CN¥472M | CN¥718M | CN¥1.31B |
| Total debt | CN¥1.98B | CN¥1.99B | CN¥2.20B | CN¥2.55B | CN¥2.40B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Kangtai Biological Products 300601.SZ | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% |
| Chongqing Zhifei Biological Products 300122.SZ | $5.28B | -1% | -28% | -210% | n/a | -6.5% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | $4.20B | -43% | +8% | -35% | n/a | n/a |
| Walvax Biotechnology 300142.SZ | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300601.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.8% | -1.1% | 8th lowest of 20 |
| 6-month return | -19.9% | -3.6% | 6th lowest of 19 |
| Distance from 52-week high | -35.8% | -33.4% | 8th lowest of 21 |
| Revenue growth (TTM) | -9.1% | +18.8% | 6th lowest of 15 |
| Operating margin | 5.8% | -58.6% | 5th highest of 15 |
| Forward P/E | 105.5× | 18.1× | most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 22.7% | -3.7% | 2nd most demanding of 5 |
| Growth delivered (Del g) | +3.4% | +33.1% | lowest of 5 |
| Hurdle (Req g minus delivered) | +19.3 pp | -32.5 pp | most demanding of 5 |
| ROIC minus cost of capital | -6.3 pp | -9.9 pp | 4th highest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% | +3.4% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | n/a | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 11.1× | -11.0% | +117.9% |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 18.1× | 3.5% | +41.4% |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | n/a | n/a | n/a |